NEW YORK (TheStreet) -- RATINGS CHANGES
Bonanza Creek (BCEI) was upgraded at Topeka Capital to buy from hold. Twelve-month price target is $68. Wattenberg acquisition should be highly accretive to earnings, Topeka Capital said.
Bio-Rad Laboratories (BIO) was downgraded to hold at TheStreet Ratings.
Cepheid (CPHD) was upgraded at Needham to buy from hold. Twelve-month price target is $50. More positive on the company, following meetings with management, Needham said.
CIT Group (CIT) was downgraded to sell at TheStreet Ratings.
Guidewire (GWRE) was upgraded at Citigroup to neutral. Twelve-month price target is $43. Expectations have come in and company fundamentals are improving, Citigroup said.
Palo Alto (PANW) was upgraded at Nomura to buy from neutral. Twelve-month price target is $80. See fewer risks around the Juniper litigation, Nomura said.
Pharmacyclics (PCYC) was downgraded at RBC Capital to sector perform from outperform. Twelve-month price target is $95. Company is facing potential growth headwinds, RBC Capital said.
Staples (SPLS) was downgraded at Goldman Sachs to sell. Twelve-month price target is $11. Company is facing margin pressure, Goldman said.
Editor's note: To see analysts' stock comments and changes to price targets and earnings estimates, go to "Street Notes" which is available only to Real Money subscribers. To find out how to become a subscriber, please click here.
>>Read More: Apple's 'Smart Home' Levels Android All Over Again